KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) Equity Average (2021 - 2025)

Historic Equity Average for Aurinia Pharmaceuticals (AUPH) over the last 5 years, with Q3 2025 value amounting to $350.5 million.

  • Aurinia Pharmaceuticals' Equity Average fell 684.89% to $350.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $350.5 million, marking a year-over-year decrease of 684.89%. This contributed to the annual value of $377.7 million for FY2024, which is 356.87% down from last year.
  • Latest data reveals that Aurinia Pharmaceuticals reported Equity Average of $350.5 million as of Q3 2025, which was down 684.89% from $342.7 million recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' Equity Average registered a high of $463.6 million during Q1 2022, and its lowest value of $315.2 million during Q3 2021.
  • Over the past 5 years, Aurinia Pharmaceuticals' median Equity Average value was $383.8 million (recorded in 2023), while the average stood at $383.7 million.
  • Its Equity Average has fluctuated over the past 5 years, first soared by 3438.36% in 2022, then tumbled by 1416.84% in 2023.
  • Quarter analysis of 5 years shows Aurinia Pharmaceuticals' Equity Average stood at $388.6 million in 2021, then grew by 6.64% to $414.4 million in 2022, then decreased by 7.12% to $384.9 million in 2023, then fell by 0.57% to $382.7 million in 2024, then fell by 8.41% to $350.5 million in 2025.
  • Its Equity Average was $350.5 million in Q3 2025, compared to $342.7 million in Q2 2025 and $363.8 million in Q1 2025.